FMR LLC Cuts Prelude Therapeutics Stake to 0.630%
Ticker: PRLD · Form: SC 13G/A · Filed: Jan 10, 2024 · CIK: 1678660
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, stake-reduction, SC-13G/A, biotech
TL;DR
**FMR LLC just dumped a ton of Prelude Therapeutics stock, now owns less than 1%.**
AI Summary
FMR LLC, a major investment firm, and its CEO, Abigail P. Johnson, have significantly reduced their stake in Prelude Therapeutics Inc. As of January 10, 2024, their beneficial ownership dropped to 264,686 shares, representing only 0.630% of the common stock. This matters to investors because a large institutional investor like FMR LLC reducing its position could signal a loss of confidence in Prelude Therapeutics' future prospects, potentially impacting the stock price negatively.
Why It Matters
A major institutional investor like FMR LLC reducing its holdings can signal a lack of confidence in Prelude Therapeutics, potentially leading other investors to re-evaluate their positions.
Risk Assessment
Risk Level: medium — While not a complete exit, a significant reduction by a major institutional holder like FMR LLC can indicate potential underlying issues or a change in investment strategy, posing a moderate risk to current and prospective investors.
Analyst Insight
A smart investor would investigate the reasons behind FMR LLC's significant reduction in their Prelude Therapeutics holdings and consider if this signals a fundamental change in the company's outlook before making any investment decisions.
Key Numbers
- 264,686 — Shares Beneficially Owned (This is the total number of Prelude Therapeutics shares FMR LLC and Abigail P. Johnson now own.)
- 0.630% — Percent of Class (This represents the small percentage of Prelude Therapeutics' common stock now held by FMR LLC and Abigail P. Johnson.)
Key Players & Entities
- FMR LLC (company) — reporting person and parent holding company
- Abigail P. Johnson (person) — reporting person, likely CEO of FMR LLC
- Prelude Therapeutics Inc (company) — the issuer of the common stock
- 264,686 (dollar_amount) — shares beneficially owned by FMR LLC and Abigail P. Johnson
- 0.630% (dollar_amount) — percentage of class beneficially owned by FMR LLC and Abigail P. Johnson
Forward-Looking Statements
- Prelude Therapeutics' stock price may experience downward pressure due to FMR LLC's reduced stake. (Prelude Therapeutics Inc.) — medium confidence, target: Next 3-6 months
- Other institutional investors might review their positions in Prelude Therapeutics following FMR LLC's divestment. (Institutional Investors) — medium confidence, target: Next 1-3 months
FAQ
Who is the reporting person in this SC 13G/A amendment?
The reporting persons are FMR LLC and Abigail P. Johnson, as stated in Item 1 of the filing.
What is the CUSIP number for Prelude Therapeutics Inc. common stock?
The CUSIP number for Prelude Therapeutics Inc. common stock is 74065P101, as specified in the filing.
What percentage of Prelude Therapeutics Inc. common stock does FMR LLC now beneficially own?
FMR LLC now beneficially owns 0.630% of Prelude Therapeutics Inc. common stock, as detailed in Item 11 for FMR LLC and Item 4(b) for the total ownership.
How many shares does Abigail P. Johnson have sole power to vote or direct the vote for?
Abigail P. Johnson has sole power to vote or direct the vote for 0 shares, as indicated in Item 5 of her reporting section.
What is the address of Prelude Therapeutics Inc.'s principal executive offices?
The address of Prelude Therapeutics Inc.'s principal executive offices is 200 POWDER MILL ROAD, WILMINGTON, DE 19803 USA, as listed in Item 1(b) of the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 10, 2024 by Abigail P. Johnson regarding Prelude Therapeutics Inc (PRLD).